Vokanamet approved in the EU for treatment of adults with type 2 diabetes Janssen-Cilag International NV announced that the European Commission has approved VOKANAMET in the European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control. Canagliflozin as a single agent was approved as INVOKANA in the European Union in November 2013. This EC decision follows a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency, recommending the approval of canagliflozin and immediate release metformin hydrochloride fixed dose combination therapy, in February. Janssen is a subsidiary of Johnson & Johnson.
News For JNJ From The Last 14 Days
Check below for free stories on JNJ the last two weeks.